Enterprise Trust & Investment’s Vertex Pharmaceuticals VRTX Stock Holding History

Enterprise Trust & Investment’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$4.17M	Sell	14,808 -82	-0.6%	-$21.9K	1.74%	16
2022 Q1	$3.89M	Sell	14,890 -450	-3%	-$107K	1.39%	22
2021 Q4	$3.37M	Buy	15,340 +7,415	+94%	+$1.44M	1.18%	25
2021 Q3	$1.44M	Hold	7,925	–	–	0.58%	48
2021 Q2	$1.6M	Sell	7,925 -25	-0.3%	-$5.23K	0.65%	44
2021 Q1	$1.71M	Sell	7,950 -25	-0.3%	-$5.49K	0.76%	38
2020 Q4	$1.83M	Buy	7,975 +5,975	+299%	+$1.37M	0.86%	36
2020 Q3	$162K	Buy	+2,000	New	+$552K	0.09%	75

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Enterprise Trust & Investment's VRTX Position: Q2 2022 in Review

Enterprise Trust & Investment reduced its Vertex Pharmaceuticals (VRTX) stake by 0.55% in Q2 2022, selling an estimated $21.9K and leaving 14,808 shares worth $4.17M. The position accounts for 1.74% of the portfolio, ranked #16.

Enterprise Trust & Investment first reported a position in VRTX in Q3 2020 and has held it in 8 quarters since. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

Enterprise Trust & Investment held 14,808 shares of Vertex Pharmaceuticals worth $4.17M as of Q2 2022.
Enterprise Trust & Investment sold 82 Vertex Pharmaceuticals shares in Q2 2022, an estimated $21.9K.
Vertex Pharmaceuticals made up 1.74% of Enterprise Trust & Investment's portfolio in Q2 2022, its #16 holding.
Enterprise Trust & Investment first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 8 quarters since.
1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Enterprise Trust & Investment's 13F filing for Q2 2022, filed 22 Jul 2022.